Bioventus reported 1Q25 orthopedic sales of $111 million, up 6% compared to the first quarter of 2024.
DUROLANE’s double-digit growth drove the company’s performance in Pain and Joint treatments. Overall, however, the category faced challenging prior-year comparisons and benefitted from a competitor’s supply issues in the second quarter of last year. Bioventus expects growth to accelerate in the second half of 2025.
Bioventus announced it is expanding its pain treatment portfolio with the addition of platelet-rich plasma systems as the exclusive U.S. distributor of XCELL PRP systems from APEX Biologix. The revenue impact in 2025 is expected to be immaterial.
Likewise, massive comps from last year caused an expected slowdown in bone graft substitutes, but the category will accelerate in the second half on the strength of recently added distributors.
Exogen grew 4% and could sustain that level of growth through 2025.
Bioventus reiterated its 2025 guidance of total revenue organic growth between 6% and 8%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
Segment
1Q25
1Q24
$ Chg
% Chg
Orthobiologics
$89.0
$85.2
$3.8
4.5%
Other
$22.0
$19.5
$2.5
12.8%
Total
$111.0
$104.7
$6.3
6%
Orthopedic Sales by Geography
Region
1Q25
1Q24
$ Chg
% Chg
US
$99.0
$93.0
$6.0
6.4%
OUS
$12.0
$11.6
$0.3
2.9%
Total
$111.0
$104.7
$6.3
6%
Company Earnings
Amt
% of Sales
Sales
$123.9
Cost of Sales
$40.8
33%
Selling and Admin
$73.5
59.3%
R&D
$3.0
2.4%
R&D
$3.0
2.4%
Other
$9.2
7.4%
Bioventus reported 1Q25 orthopedic sales of $111 million, up 6% compared to the first quarter of 2024.
DUROLANE's double-digit growth drove the company's performance in Pain and Joint treatments. Overall, however, the category faced challenging prior-year comparisons and benefitted from a competitor's supply issues in the second quarter of...
Bioventus reported 1Q25 orthopedic sales of $111 million, up 6% compared to the first quarter of 2024.
DUROLANE’s double-digit growth drove the company’s performance in Pain and Joint treatments. Overall, however, the category faced challenging prior-year comparisons and benefitted from a competitor’s supply issues in the second quarter of last year. Bioventus expects growth to accelerate in the second half of 2025.
Bioventus announced it is expanding its pain treatment portfolio with the addition of platelet-rich plasma systems as the exclusive U.S. distributor of XCELL PRP systems from APEX Biologix. The revenue impact in 2025 is expected to be immaterial.
Likewise, massive comps from last year caused an expected slowdown in bone graft substitutes, but the category will accelerate in the second half on the strength of recently added distributors.
Exogen grew 4% and could sustain that level of growth through 2025.
Bioventus reiterated its 2025 guidance of total revenue organic growth between 6% and 8%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
Segment
1Q25
1Q24
$ Chg
% Chg
Orthobiologics
$89.0
$85.2
$3.8
4.5%
Other
$22.0
$19.5
$2.5
12.8%
Total
$111.0
$104.7
$6.3
6%
Orthopedic Sales by Geography
Region
1Q25
1Q24
$ Chg
% Chg
US
$99.0
$93.0
$6.0
6.4%
OUS
$12.0
$11.6
$0.3
2.9%
Total
$111.0
$104.7
$6.3
6%
Company Earnings
Amt
% of Sales
Sales
$123.9
Cost of Sales
$40.8
33%
Selling and Admin
$73.5
59.3%
R&D
$3.0
2.4%
R&D
$3.0
2.4%
Other
$9.2
7.4%
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
